PUMA BIOTECHNOLOGY, INC.

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 TTM
Total Revenue $958k
$27.7m +2789.87%
$251.0m +806.60%
$272.3m +8.47%
$225.1m -17.32%
$253.2m +12.46%
$228.0m -9.92%
$235.6m +3.34%
$230.5m -2.19%
$228.4m -0.91%
$231.2m +1.26%
Cost of Revenue $207k
$5.6m +2594.55%
$34.6m +521.34%
$36.8m +6.34%
$39.4m +6.95%
$63.7m +61.78%
$55.1m -13.51%
$62.7m +13.77%
$64.4m +2.75%
$58.2m -9.70%
$58.2m +0.07%
Cost of sales $207k
$5.6m +2594.55%
$34.6m +521.34%
$36.8m +6.34%
$39.4m +6.95%
$63.7m +61.78%
$55.1m -13.51%
$62.7m +13.77%
$64.4m +2.75%
$58.2m -9.70%
$58.2m +0.07%
Gross Profit (Calculated) (derived) $751k
$22.1m +2843.64%
$216.4m +878.47%
$235.4m +8.82%
$185.7m -21.11%
$189.5m +2.00%
$172.9m -8.72%
$173.0m +0.01%
$166.1m -3.98%
$170.2m +2.50%
Research and Development Expense $222.8m $207.8m $164.9m $132.9m $97.7m $71.9m $52.2m $50.4m $54.9m $62.1m $71.4m
General and Administrative Expense $53.8m $106.7m $146.2m $141.7m $118.5m $116.3m $90.0m $89.9m $80.2m $70.8m $71.4m
Amortization of Intangible Assets $1.6m $3.9m $3.9m $6.3m $8.0m $8.0m $9.7m $9.7m $9.7m
Operating Lease, Expense $5.1m $4.9m $4.9m $4.9m $4.5m
Operating Expenses $276.6m $320.1m $345.7m $311.4m $255.5m $251.9m $204.3m $203.0m $199.5m $191.1m $200.8m
Total operating costs and expenses $276.6m $320.1m $345.7m $311.4m $255.5m $251.9m $204.3m $203.0m $199.5m $191.1m
Operating Income (Loss) ($276.6m)
($292.4m) -5.71%
($94.7m) +67.62%
($39.1m) +58.70%
($30.4m) +22.24%
$1.3m +104.24%
$23.7m +1738.76%
$32.6m +37.61%
$31.0m -5.13%
$37.3m +20.45%
$30.4m -18.40%
Interest income $958k $1.3m $1.8m $2.8m $489k $160k $813k $2.6m $4.7m $4.1m $3.9m
Other Nonoperating Income (Expense) ($373k) ($101k) ($714k) $128k $367k $292k ($28k) $759k $862k $1.0m
Other income ($373k) ($101k) ($714k) $128k $367k $292k ($28k) $759k $862k $1.0m
Interest Expense (non-operating) $720k $11.0m $15.0m $14.0m $12.8m $11.6m $13.3m $12.5m $6.6m $3.5m
Total other expenses, net $585k $435k ($18.9m) ($36.5m) ($29.4m) ($30.1m) ($23.3m) ($10.0m) ($6.9m) ($1.5m)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest ($113.6m) ($75.5m) ($59.8m) ($28.8m) $457k $22.7m $24.1m $35.8m $31.2m
Current Income Tax Expense (Benefit) $324k $455k $1.1m $897k $1.4m $4.5m
Deferred income tax (expense) benefit $0 $0 $7.1m ($3.2m)
Income Tax Expense (Benefit) $0 $0 $17k $53k $207k $324k $455k $1.1m ($6.2m) $4.7m $4.5m
Net Income (Loss) Attributable to Parent ($276.0m)
($292.0m) -5.78%
($113.6m) +61.10%
($75.6m) +33.44%
($60.0m) +20.64%
($29.1m) +51.45%
$2k +100.01%
$21.6m +1079450.00%
$30.3m +40.23%
$31.1m +2.75%
$26.7m -14.12%
Earnings Per Share, Basic ($29,126.00) $0.00 $0.46 $0.62 $0.62 $0.53
Earnings Per Share, Diluted ($8.29) ($7.85) ($2.99) ($1.95) ($1.52) ($0.72) $0.00 $0.45 $0.62 $0.61 $0.51
Weighted Average Number of Shares Outstanding, Basic 39.6m 40.6m 44.7m 47.1m 48.6m 50.0m 50.6m
Weighted-average shares of common stock outstanding—basic (in shares) 39.6m 40.6m 44.7m 47.1m 48.6m 50.0m 50.6m
Weighted-average shares of common stock outstanding—diluted (in shares) 39.6m 40.6m 44.9m 47.6m 49.1m 50.7m 50.6m
Weighted Average Number of Shares Outstanding, Diluted 39.6m 40.6m 44.9m 47.6m 49.1m 50.7m 51.8m